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Increasing evidence suggests an association between ele-
vated serum aminotransferase level and the metabolic syn-
drome. However, the significance of relatively low levels of
aminotransferase in relation to the metabolic syndrome has not
been fully investigated in the general population. We inves-
tigated the association between serum amiontransferase level
and the metabolic syndrome using data from a nationwide
survey in Korea. We measured serum aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) levels and
metabolic conditions among 9771 participants aged 20 or more
in the 1998 and 2001 Korean National Health and Nutrition
Examination Surveys. Metabolic syndrome was defined
according to NCEP-ATP III criteria with a modified waist cir-
cumference cutoff (men > 90 cm; women > 80 cm). Serum
aminotransferase level, even within normal range, was asso-
ciated with the metabolic syndrome independent of age, body
mass index, waist circumference, smoking, and alcohol intake.
Compared with the lowest level (< 20 IU/L), the adjusted
odds ratios (95% CI) for an AST level of 20-29, 30-39, 40-49
and 50 IU/L were 1.10 (0.85-1.42), 1.37 (1.02-1.83), 1.62
(1.08-2.43), and 2.25 (1.47-3.44) in men, and 1.18 (0.99-1.41),
1.43 (1.29-1.83), 1.71 (1.09-2.68), and 2.14 (1.20-3.80) in
women, respectively. Corresponding odds ratios for ALT levels
were 1.27 (0.99-1.63), 1.69 (1.28-2.23), 2.17 (1.58-2.99), and
2.65 (1.96-3.58) in men, and 1.44 (1.22-1.70), 1.65 (1.26-2.15),
2.94 (1.93-4.47), and 2.25 (1.54-3.30) in women, respectively.
In conclusion, elevated serum aminotransferase levels, even in
the normal to near normal range, are associated with features
of the metabolic syndrome.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is an
increasingly recognized condition that has accom-
panied the recent increase in obesity.
1-3 and is also
known to be associated with various cardiovas-
cular risk factors including central obesity, type 2
diabetes, dyslipidemia, and high blood pres-
sure.
2,4-9 Moreover, it has been suggested that
NAFLD can be considered a hepatic consequence
of the metabolic syndrome.
10-14 Patients with fatty
liver disease usually have elevated serum amino-
transferase activity, and so aminotransferase as-
says are widely used to monitor liver function in
people with metabolic syndrome.
1,2 It has been sug-
gested, however, that the use of current definitions
of normal serum aminotransferase levels may un-
derestimate the prevalence of liver disease, because
normal aminotransferase levels cannot rule out the
existence of liver disease.
15-17 The significance of
serum amiontransferase level, including within the
normal to near normal range, needs to be reviewed
in relation to the metabolic syndrome, and the
need for a full investigation in the general popula-
tion still remains. Accordingly, we investigated the
independent association between serum amino-
transferase level and the metabolic syndrome in a
representative Korean population.
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MATERIALS AND METHODS
Study population
The Korean National Health and Nutrition
Examination Surveys were conducted in non-insti-
tutionalized Korean civilians in 1998 and 2001. A
stratified multistage probability sampling design
was used, with selection made from sampling
units based on geographical area, sex, and age
groups using household registries. A total of
13,451 individuals (7945 in 1998 and 5506 in 2001)
aged 20 years or more completed the health
examinations. Among them, 11,282 people fasted
for at least eight hours before their blood samples
were obtained. We excluded 549 people who
tested positive for Hepatitis B (HBsAg), and 95
pregnant women. We also excluded 389 people
who reported consuming at least 50 g of alcohol
per day. In the end, 9771 people (4019 men and
5752 women) were eligible for our analyses.
Data collection
Anthropometric measurements including height,
weight, and waist and hip circumference were
conducted by well-trained examiners on individ-
uals wearing light clothing. Waist circumference
was measured to the nearest 0.1 cm at the mid-
point between the lower borders of the rib cage
and the iliac crest. A standard mercury sphygmo-
manometer was used to measure the blood
pressure of each individual in a sitting position
after a 10-minute rest period. Systolic and dias-
tolic blood pressures were measured at phase I
and V Korotkoff sounds, respectively. Two
readings of systolic and diastolic blood pressure
were recorded and the average was used for data
analysis. Blood samples were obtained after an
overnight fasting period and subsequently an-
alyzed at a central certified laboratory. Serum
glucose, total cholesterol, triglyceride, high den-
sity lipoprotein (HDL)-cholesterol, aspartate ami-
notransferase (AST), and alanine aminotransferase
(ALT) levels were measured by an autoanalyzer
(Hitachi 747, Tokyo, Japan). Smoking and alcohol
consumption habits and current medication status
were determined by a self-administered question-
naire. Non-drinkers were people who reported
that they never or almost never (less than once a
month) consumed alcoholic beverages. For
drinkers, daily alcohol intake was calculated by
multiplying the frequency of drinking and the
amount consumed in one sitting.
Definition of the metabolic syndrome
The metabolic syndrome was defined according
to the National Cholesterol Education Program
Adult Treatment Panel III (NCEP-ATP III), except
for abdominal obesity by waist circumference.
18
We used a modified waist circumference cutoff of
> 90 cm in men and > 80 cm in women.
19 Hence,
in the present study, individuals having three or
more of the five following criteria were defined as
having the metabolic syndrome: 1) high blood
pressure ( 130/85 mmHg) or anti-hypertensive
medication, 2) elevated fasting blood glucose (
6.1 mmol/L) or anti-diabetic medication, 3) hyper-
triglyceridemia ( 1.7 mmol/L), 4) low HDL-cho-
lesterol (men, <1.0mmol/L; women, < 1.3 mmol/
L), and 5) abdominal obesity by waist circum-
ference (men, > 90 cm; women, > 80 cm).
Statistical analysis
We compared clinical and biochemical charac-
teristics between men and women using student's
t-test or 
2 test. Spearman correlation coefficients
among the metabolic risk factors and aminotrans-
ferase levels were calculated in men and women
separately. The sex-specific prevalence of abnor-
mal metabolic conditions and the metabolic
syndrome were calculated by the level of AST and
ALT. Independent association between serum
aminotransferase level and the metabolic syn-
drome was investigated using serial logistic
regression models. First, we estimated the age-
adjusted odds ratio for the metabolic syndrome by
serum aminotransferase levels. Second, we ad-
justed for age, body mass index, cigarette smoking
and alcohol intake. Finally, waist circumferences
were adjusted in addition to all of the variables
in the second model. In order to assess the
possible confounding effects of alcohol intake, we
investigated the association between ALT and the
metabolic syndrome by drinking status.Hyeon Chang Kim, et al.
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RESULTS
Clinical characteristics and laboratory data of
the 4019 men and 5752 women are shown in Table
1. Mean age was 44.7 years for men and 45.6 years
for women (p = 0.009), but mean body mass index
was the same for both sexes. Compared with
women, men had higher waist circumference,
blood pressure, fasting glucose, triglyceride, AST
and ALT levels, but lower HDL-cholesterol levels.
Among the study participants, 6.6% were taking
anti-hypertensive medications, and 2.6% were
taking anti-diabetic medications. Of men, 61.5%
were current smokers, as were 5.7% of women.
Regular alcohol drinkers comprised 64.8% of men
and 28.1% of women.
Serum aminotransferase levels were correlated
with most metabolic risk factors, except there was
no association (p = 0.982) between AST level and
HDL-cholesterol level in women. Compared to
AST level, serum ALT level was more closely as-
sociated with body mass index, waist circum-
ference, and fasting blood glucose level (Table 2).
Prevalence of central obesity, high blood pressure,
high fasting blood glucose, and hypertrigly-
ceridemia increased according to the increase of
Table 1. Clinical and Biochemical Characteristics of 4019 Men and 5752 Women
Characteristics Men (n = 4019) Women (n = 5752) p for difference*
Mean ± SD
Age (yr) 44.7 ± 15.1 45.6 ± 15.8 0.009
Body mass index, kg/m
2 23.3 ± 3.0 23.3 ± 3.3 0.805
Waist circumference, cm 83.2 ± 8.3 78.4 ± 9.5 < 0.001
Systolic blood pressure, mmHg 126.7 ± 18.1 122.6 ± 20.6 < 0.001
Diastolic blood pressure, mmHg 80.4 ± 11.3 75.9 ± 11.4 < 0.001
Fasting glucose, mmol/L 5.59 ± 1.47 5.51 ± 1.47 0.008
Total cholesterol, mmol/L 4.87 ± 0.94 4.87 ± 0.95 0.924
Triglyceride, mmol/L 1.61 ± 0.82 1.31 ± 0.69 < 0.001
HDL-cholesterol, mmol/L 1.19 ± 0.29 1.29 ± 0.30 < 0.001
Aspartate aminotransferase, IU/L 28.1 ± 21.0 23.0 ± 8.9 < 0.001
Alanine aminotransferase, IU/L 29.9 ± 20.7 20.1 ± 12.9 < 0.001
Number (%)
Anti-hypertensive medication 203 (5.1) 441 (7.7) < 0.001
Anti-diabetic medication 91 (2.3) 163 (2.8) 0.082
Cigarette smoking
Nonsmoker 786 (19.6) 5311 (92.3) < 0.001
Ex-smoker 762 (19.0) 111 (1.9)
Current smoker 2471 (61.5) 330 (5.7)
Alcohol intake
Nondrinker 1414 (35.2) 4138 (71.9) < 0.001
Drinker 2605 (64.8) 1614 (28.1)
*Student’s t-test for continuous variables, and χ
2-test for categorical variables.
HDL, high density lipoprotein.Serum Aminotransferase Level and Metabolic Syndrome
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serum AST level. The prevalence of low serum
HDL-cholesterol was negatively associated with
AST level in men, but not in women. On the
contrary, serum ALT level was positively asso-
ciated with all five metabolic abnormalities in
both sexes (Table 3).
Table 2. Correlation Among Metabolic Risk Factors and Serum Aminotransferase Levels






BMI - 0.818 0.196 0.266 0.261 0.343 -0.270 0.146 0.123 0.353
WC 0.836 - 0.248 0.290 0.284 0.384 -0.280 0.188 0.161 0.340
SBP 0.311 0.403 - 0.660 0.133 0.169 0.028* 0.137 0.175 0.117
DBP 0.289 0.334 0.750 - 0.182 0.213 0.001 0.079 0.163 0.197
Total cholesterol 0.267 0.329 0.311 0.272 - 0.354 0.112 0.140 0.156 0.220
Triglyceride 0.332 0.413 0.346 0.281 0.424 - -0.375 0.139 0.189 0.293
HDL-cholesterol -0.220 -0.246 -0.112 -0.078 0.127 -0.421 - -0.045 0.105 -0.068
FBS 0.234 0.281 0.235 0.162 0.182 0.213 -0.110 - 0.095 0.141
AST 0.149 0.223 0.280 0.220 0.254 0.217 0.001
§ 0.118 - 0.682
ALT 0.298 0.340 0.252 0.235 0.251 0.262 -0.051 0.190 0.683 -
Figures are Spearman correlation coefficients for men in the upper right of the table, for women in the lower left of the table.
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density
lipoprotein; FBS, fasting blood sugar; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
All correlations were significant with p < 0.001, except for *p = 0.077; p = 0.954; p = 0.004;
§p = 0.928.
























Waist circumference > 90 cm 14.8 18.3 25.7 35.8 28.6 < 0.001 10.6 16.7 25.8 33.1 41.6 < 0.001
Blood pressure 130/85 mmHg* 34.4 43.8 51.8 55.3 65.9 < 0.001 39.0 43.4 48.6 53.9 55.6 < 0.001
Fasting blood glucose 6.1 mmol/L* 15.2 17.9 23.5 28.8 30.8 < 0.001 15.2 17.6 22.3 23.5 31.4 < 0.001
Triglyceride 1.7 mmol/L 26.8 35.0 47.8 54.0 55.5 < 0.001 25.2 34.0 44.3 55.5 61.6 < 0.001
HDL-cholesterol < 1.0 mmol/L 34.8 31.6 27.9 28.8 21.4 < 0.001 27.8 29.0 33.6 35.6 37.1 < 0.001
Women
Waist circumference > 80 cm 30.8 44.7 53.9 61.5 66.7 < 0.001 31.7 52.2 62.5 73.3 67.4 < 0.001
Blood pressure 130/85 mmHg* 21.0 38.7 50.3 48.1 54.3 < 0.001 27.1 43.5 43.5 54.0 50.6 < 0.001
Fasting blood glucose 6.1 mmol/L* 12.8 17.8 227 29.6 39.5 < 0.001 12.5 22.4 22.4 26.7 33.1 < 0.001
Triglyceride 1.7 mmol/L 16.7 25.4 32.7 40.0 42.0 < 0.001 17.5 309 30.9 43.3 39.3 < 0.001
HDL-cholesterol < 1.3 mmol/L 54.7 52.3 55.8 56.3 53.1 0.916 52.3 54.4 54.4 60.0 57.9 0.002
*Including people on anti-hypertensive/anti-diabetic medication.
HDL, high density lipoprotein.Hyeon Chang Kim, et al.
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Age-adjusted odds ratios for the metabolic
syndrome increased progressively according to
serum aminotransferase levels. The positive asso-
ciation between aminotransferase level and the
metabolic syndrome was observed even within
the normal range of aminotransferase levels.
When adjusted for age, body mass index, smoking
and alcohol intake, the association between
aminotransferase level and metabolic syndrome
was attenuated but still highly significant. Even
after additional adjustment for waist circum-
ference, the association between aminotransferase
level and metabolic syndrome still remained
(Table 4). We assessed the association between







Odds ratio (95% confidence interval) for metabolic syndrome
Age-adjusted Multivariate adjusted (1)* Multivariate adjusted (2)
Men
AST < 20 IU/L 776 118 (15.2%) 1.00 1.00 1.00
20-29 IU/L 2053 415 (20.2%) 1.29 (1.03 - 1.62) 1.13 (0.88 - 1.45) 1.10 (0.85 - 1.42)
30-39 IU/L 793 218 (27.5%) 1.90 (1.47 - 2.44) 1.44 (1.09 - 1.91) 1.37 (1.02 - 1.83)
40-49 IU/L 215 77 (35.8%) 2.74 (1.94 - 3.86) 1.70 (1.15 - 2.51) 1.62 (1.08 - 2.43)
50 IU/L 182 66 (36.3%) 2.70 (1.87 - 3.88) 2.52 (1.67 - 3.81) 2.25 (1.47 - 3.44)
Total 4019 894 (22.2%)
ALT < 20 IU/L 1250 154 (12.3%) 1.00 1.00 1.00
20-29 IU/L 1306 246 (18.8%) 1.65 (1.32 - 2.07) 1.32 (1.04 - 1.67) 1.27 (0.99 - 1.63)
30-39 IU/L 664 180 (27.1%) 2.98 (2.33 - 3.81) 1.89 (1.44 - 2.47) 1.69 (1.28 - 2.23)
40-49 IU/L 362 125 (34.5%) 4.40 (3.32 - 5.83) 2.41 (1.77 - 3.29) 2.17 (1.58 - 2.99)
50 IU/L 437 189 (43.3%) 6.57 (5.05 - 8.54) 3.16 (2.36 - 4.23) 2.65 (1.96 - 3.58)
Total 4019 894 (22.2%)
Women
AST < 20 IU/L 2096 367 (17.5%) 1.00 1.00 1.00
20-29 IU/L 2832 867 (30.6%) 1.31 (1.12 - 1.52) 1.25 (1.06 - 1.48) 1.18 (0.99 - 1.41)
30-39 IU/L 608 264 (40.5%) 1.62 (1.30 - 2.01) 1.47 (1.16 - 1.86) 1.43 (1.29 - 1.83)
40-49 IU/L 135 64 (47.4%) 2.40 (1.63 - 3.55) 1.81 (1.17 - 2.80) 1.71 (1.09 - 2.68)
50 IU/L 81 44 (54.3%) 3.38 (2.06 - 5.54) 2.53 (1.46 - 4.37) 2.14 (1.20 - 3.80)
Total 5752 1588 (27.6%)
ALT < 20 IU/L 3529 683 (19.4%) 1.00 1.00 1.00
20-29 IU/L 1495 549 (36.7%) 1.97 (1.70 - 2.28) 1.58 (1.35 - 1.86) 1.44 (1.22 - 1.70)
30-39 IU/L 400 178 (44.5%) 2.90 (2.30 - 3.66) 1.89 (1.46 - 2.44) 1.65 (1.26 - 2.15)
40-49 IU/L 150 86 (57.3%) 5.66 (3.93 - 8.13) 3.40 (2.26 - 5.11) 2.94 (1.93 - 4.47)
50 IU/L 178 92 (51.7%) 4.79 (3.43 - 6.70) 2.54 (1.76 - 3.67) 2.25 (1.54 - 3.30)
Total 5752 1588 (27.6%)
*Adjusted for age, body mass index, smoking, and alcohol intake; Adjusted for age, body mass index, smoking, alcohol intake,
and waist circumference.
AST, aspartate aminotransferase; ALT, alanine aminotransferase.Serum Aminotransferase Level and Metabolic Syndrome
Yonsei Med J Vol. 47, No. 4, 2006
ALT and the metabolic syndrome in non-drinkers
and drinkers separately. The positive association
between serum ALT level and the metabolic
syndrome was not different by alcohol intake (Fig.
1).
In a further analysis, we compared the relative
significance of individual liver enzymes by in-
cluding AST and ALT in the same model. In that
model, the metabolic syndrome was significantly
associated only with ALT level (p < 0.001 for both
sexes), but not with AST level (p = 0.272 for men
and 0.240 for women).
DISCUSSION
We found a positive association between serum
aminotransferase level and the metabolic syn-
drome in Korean adults. Recent epidemiologic
studies have also reported an association between
aminotransferase elevation and the metabolic syn-
drome.
20-30 This association has been observed in






30 Although similar findings have
already been reported in some Korean popula-
tions,
22,29,30 the present study showed a significant
association between aminotransferase level and
the metabolic syndrome in a nationally represen-
tative Korean population. Another more impor-
tant finding of this study is that the association
was observed even in the normal to near normal
range of aminotransferase levels, in a dose-related
manner.
The most probable explanation for the asso-
ciation between serum aminotransferase level and
the metabolic syndrome is NAFLD. NAFLD is the
most common cause of unexplained aminotrans-
ferase elevations in Western populations, and
even in some Asian populations.
2,31 A growing
body of evidence supports an association between
NAFLD and the metabolic syndrome.
3,7,10-14,30-35
Recent studies have added evidence that insulin
resistance, a key component of the metabolic
syndrome, may contribute to the development of
NAFLD.
7,13,36,37 Central obesity may be an under-
lying cause of insulin resistance and can also
contribute to the development of NAFLD.
11,37-39
Compared with adipose tissue in other sites,
visceral adipose tissue is more resistant to insulin,
and the associated relative hyperinsulinemia
promotes lipogenesis in the liver.
40,41 Visceral adi-
pose tissue is also known to be a potent modu-
lator of insulin action on hepatic glucose pro-
duction and gene expression.
42 In the present
study, serum aminotransferase levels had a dose-
related association with metabolic syndrome even
after adjustment for body mass index and waist
circumference. The significance of central obesity
in the connection between liver dysfunction and
the metabolic syndrome may differ by ethnicity,
as differences in the adverse effects of obesity
between different ethnicities have been re-
ported.
43,44 Further studies are required to inves-
Fig. 1. Association between serum alanine aminotransferase level and metabolic syndrome by alcohol drinking status. Odds
ratios with 95% confidence intervals (vertical lines) are adjusted for age, body mass index, waist circumference, and
smoking status.Hyeon Chang Kim, et al.
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tigate ethnic and regional differences in the rela-
tionship between liver disease and the metabolic
syndrome.
Other conditions which can increase amino-
transferase activity may also be associated with
the metabolic syndrome.
31 The serum aminotrans-
ferase assay is a sensitive screening tool for the
detection of liver disease, but it cannot provide
information on the underlying causes of liver
damage. Alcohol-related liver disease can be asso-
ciated with the metabolic syndrome. Heavy
drinkers tend to have an adverse cardiovascular
risk profile, including high blood pressure, central
obesity, and unhealthy lifestyle. We did not
include current heavy drinkers for the analysis,
and past history of alcohol consumption was also
not considered. We could not exclude other causes
of aminotransferase elevation, such as C-viral
hepatitis and iron overload. It is unlikely that
other causes of liver disease severely affected the
relationship between aminotransferase levels and
the metabolic syndrome. A recent study found
that the association between metabolic risk factors
and ALT elevation was similar in subjects with
and without identifiable causes of chronic liver
disease, including viral hepatitis, excessive alcohol
use, and increased iron saturation.
45 Some sys-
temic diseases and medications may also elevate
serum aminotransferase levels. Accordingly, we
performed further analysis after excluding 963
people who were receiving hormone replacement
therapy or medications for hypertension, diabetes
mellitus, liver disease, and/or renal disease
during the month before examinations. We still
found a strong association between serum amino-
transferase level and the metabolic syndrome,
even in the normal to near normal range of
aminotransferase. Compared with levels below 20
IU/L, the adjusted odds ratios for an ALT level
of 20-29, 30-39, 40-49 and 50 IU/L were 1.38,
1.76, 2.24 and 3.01 in men and 1.49, 1.73, 3.05 and
2.40 in women, respectively (p < 0.05 for all).
These results demonstrate that other causes of
aminotransferase elevations did not alter the out-
comes of this study.
In the present study, serum ALT level was more
closely associated with the metabolic syndrome
than AST level. In addition to that, only ALT level
was significantly associated with the metabolic
syndrome when both enzymes were simultane-
ously investigated in a single model. This finding
is in agreement with previous studies, and can be
explained by higher specificity of ALT to liver
disease.
Serum aminotransferase assays have been
widely used to identify NAFLD and other liver
diseases. But the cutoff level that discriminates
between healthy and diseased livers has not been
clearly defined. The upper normal limit of serum
aminotransferase is set on average at 40 IU/L,
ranging from 30-50 IU/L.
17,46 However, this nor-
mal range was calculated from a supposedly
healthy reference population, which probably
included people with mild to moderate chronic
liver disease. Several previous studies have de-
monstrated that serum aminotransferase level,
even within the normal range, may be associated
with morbidity and mortality.
15-17,22,29,47 The pro-
gressive linear association between serum amino-
transferase level and the metabolic syndrome
suggests that people with high normal amino-
transferase levels may need further investigation
for the presence of fatty liver disease. Adjustment
of the normal limit of serum amiontransferase
should be considered for the monitoring of liver
function in people with the metabolic syndrome.
In most Western regions, the aminotransferase
assay has been less useful as a mass-screening
tool, because the prevalence of liver disease is
lower than in East Asian or African countries.
However, considering the increasing prevalence
of the metabolic syndrome and its association
with liver dysfunction, the significance of the
serum aminotransferase assay needs to be re-
evaluated.
The present study also has several possible
limitations. First, we had only one measurement
of aminotransferase. Aminotransferase activity is a
sensitive marker of liver dysfunction, but its
specificity in detection of liver diseases is low
because it can be elevated temporarily in various
conditions. This limitation would serve to attenu-
ate the magnitude of the association toward the
null; thus, our results can probably be considered
as conservative estimates. Second, there is the
possibility of confounding effects by viral and
alcoholic liver diseases. We excluded people who
were positive for HBsAg, but could not rule outSerum Aminotransferase Level and Metabolic Syndrome
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the effects of other types of viral hepatitis. We did
not include heavy drinkers in the analysis and
statistically controlled the effects of alcohol con-
sumption, but the possibility of residual con-
founding influence still exists. Finally, this study
could not investigate the causal relationship
between serum aminotransferase levels and the
metabolic syndrome because of its cross-sectional
design. Further prospective studies are needed to
establish the temporal relationship between ami-
notransferase level and the metabolic syndrome,
and to discover the underlying mechanism of the
relationship.
In conclusion, serum aminotransferase levels
even in the normal or near normal range are asso-
ciated with features of the metabolic syndrome in
Korean men and women.
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